Comparing Novavax's COVID Vaccine to Pfizer and Moderna: What You Need to Know

Novavax, the fourth COVID-19 vaccine option in the U.S., has been authorized for use as a primary vaccine series since early 2022 and recently as a booster for anyone ages 12 or older. It is a protein/adjuvant vaccine that includes a fully formed spike protein, unlike mRNA vaccines. Studies suggest that Novavax has comparable efficacy to Moderna and Pfizer vaccines, with around 55% effectiveness against symptoms and 28% effectiveness against infection during the Omicron wave. Mixing Novavax with mRNA vaccines may provide more durable protection, but further studies are needed. Novavax may have fewer side effects, but conclusive evidence is lacking. To get Novavax, individuals can check vaccines.gov or visit large pharmacy chains like Costco and CVS.